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Identification of a single base insertion in the COL4A5 gene in Alport
syndrome. We identified a novel mutation in the COL4AS gene of a
Japanese patient with Alport syndrome. A combination of in vitro
amplification of the exons with single strand conformation polymor-
phisms (SSCP) analysis suggested the presence of a mutation in exon
48. Sequencing of the amplified DNA revealed a single base (T)
insertion which was between nucleotides T 4750 and G 4751 within the
methionine 1516. This mutation caused a shift in the reading frame of
nine amino acids and introduced a premature termination signal that
would be expected to lack about two-thirds of the noncollagenous
(NCI) domain. This mutation may interfere with type IV collagen
assembly leading to increased permeability and play a causative role in
the glomerular basement membrane abnormality of this patient with
typical Alport syndrome. Gene tracking by restriction enzyme NlaIII
digestion revealed that the patient's mother is heterozygous whereas
the patient's brother and one sister are normal, albeit they have
hematuria and proteinuria. Without gene analysis, they would have
been misdiagnosed. We propose that the diagnosis of Alport syndrome
should be made on the basis of both clinical phenotypes and molecular
defects.
Alport syndrome [1] is an inherited, progressive hematuric
kidney disease often accompanied by high-tone sensorineural
deafness and eye lesions (lenticonus and macula flecks). Carrier
females have a variable and generally milder clinical course [2].
Alport syndrome is characterized by abnormalities in the gb-
merular basement membrane (GBM) as diffuse irregularly
thickening with splitting of the lamina densa. Ultrastructural
findings and immunological evidence led to the suggestion that
the principal defect in Alport syndrome was due to a complete
absence of, or alterations in an a chain of type IV collagen, a
major structural component of the GBM [3—6]. The COL4A5
gene mapped to Xq22, encoding a newly found chain (a5) [7, 8],
was confirmed to be the Alport syndrome locus, based on
findings of several mutations, single base mutations [9—14] and
major rearrangements such as large deletions [13, 15—17] and
duplication [161. Full-length cDNA clones providing the com-
plete amino acid sequence of the a5(IV) collagen have been
isolated and characterized [11].
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In our analysis of part of the 3 '-end of the COL4A5 gene in
Japanese patients with Alport syndrome, we noted a novel
mutation of a single base insertion in exon 48 of the gene.
Methods
Patient
Patient OYM was a 15-year-old Japanese male with Alport
syndrome accompanied by sensorineural deafness. At age 18
months, he experienced gross hematuria, upper respiratory
infection and high fever. The proteinuria and hematuria had
been persistent and as it advanced gradually, nephrotic syn-
drome was suspected (proteinuria, 2 g/day; serum albumin, 2.3
g/dl; serum cholesterol, 225 mgldl) at age five years. At this
time, electron microscopic examination of glomeruli obtained
by the renal biopsy revealed that the lamina densa of GBM had
widened and split into several layers, which were findings
compatible with the GBM of Alport syndrome (Fig. IA). The
GBM did not react with Goodpasture serum by immunofluo-
rescence microscopy. Bilateral high tone sensorineural deaf-
ness was also present, but the eyes were unaffected. Renal
function further deteriorated when he was 12 years old; over 1.2
mg/dl of serum creatinine (current data, 4.0 mg/dl).
Hematuria, proteinuria, and renal dysfunction are present in
the mother of the patient. Three maternal uncles had had renal
failure at about 18 years of age; two died at age 20 years and one
underwent transplantation. One of two maternal aunts had had
renal failure and was treated with hemodialysis, while the other
one is healthy. In the patient's sister, age 16 years, hematuria
and proteinuria were first evident when she was six years old.
Renal biopsy specimens obtained then revealed minimal gb-
merular abnormalities (light microscopy) and no splitting of
GBM indicating Alport syndrome (electron microscopy; Fig.
1B). At present, she has hematuria (1+) and mild proteinuna
(+1—) by a dipstick, and serum creatinine is 0.4 mg/dl. The
patient's brother, 12 years old, was found to have hematuria at
age two years and developed proteinuria later. Renal his-
topathological examination could not be done as the mother
refused permission (because we told her findings of his gene
analysis, as discussed later). At present, he has hematuria (1+)
and proteinuria (1+) by a dipstick, and serum creatinine is 0.3
mgldl. Sensorineural deafness and eye lesions are absent in two
siblings. The father was not examined.
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Fig. 1. Electron micrograph of renal biopsy specimens. A. Patient's GBM shows diffuse irregular thickening with splitting and splintering with
small round electron-dense granulation of the lamina densa, compatible with GBM of Alport syndrome (x 12,600). B. GBM of patient's sister has
a normal lamina densa and foot process, and with no evidence of Alport syndrome (x8,lOO).
FIg. 2. Structure of the 3' end of the
COL4A5 gene and cDNA clones and
________
synthetic oligonucleotide primers. A.
Diagram of the gene with exons indicated by
shaded boxes and introns indicated by a
solid line. The exons are numbered from the
5' end. The location of 8 oligonucleotide
primers are indicated by arrows. Three
types of cDNA clones HSI9 (0.8 kb), HS3
(1.3 kb), and HS2O (1.7 kb) obtained by
screening are indicated above. Scale of 5 kb
in the gene is below, B. Sequences of eight
oligonucleotide primers.
Methods
Oligonucleotide primers were synthesized on a 391 DNA
Synthesizer (Applied Biosystems, USA) based on the sequence
of the COL4A5 gene [18]. A human placental cDNA library in
Agtl 1 (Clontech) was screened using, as the probe, a poly-
merase chain reaction (PCR) products mixture amplified with
four pairs of primers; 35A and 36B, 43A and 45B, 48A and 49B,
and SOA and 51B (Fig. 2). Human placental and leukocyte
genomic DNA libraries (Clontech) were screened using, as a
probe, amplified DNA with primers 48A and 48B (Fig. 3). The
probes were labeled with 32P-dCTP using the random priming
method [19]. Positive clones were isolated, and subcloned into
the pUC18 vector. Double stranded DNA was sequenced by the
dideoxy chain termination method [20] using Sequenase Ver-
sion 2.0 DNA Sequencing Kits (USB).
Genomic DNA was extracted from heparinized peripheral
blood cells from the patient using the standard method [21].
Genomic DNA was amplified in vitro by PCR [22, 23]. PCR was
carried out on a thermal cycler (Perkin Elmer Cetus) using 0.1
g of genomic DNA as template and primers at 50 pmol
concentration. Taq DNA polymerase (2.5 U, Boehringer Mann-
heim) was added and 30 cycles were carried out as follows:
denaturation at 94°C for one minute, annealing at 55°C for one
minute, and extension at 72°C for three minutes.
For Southern blot analysis, genomic DNA (10 g) was
digested with EcoRI, electrophoresed on a 0.5% agarose gel,
transferred to a nitrocellulose filter, and hybridized with the
32P-labeled normal human COL4AS cDNA that was the 0.8 kb
fragment spanning exons 47 to 51 (Fig. 2). Conditions were as
described elsewhere [24].
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We isolated the genomic clone (1.5 kb) containing exon 48
from genomic libraries and determined the flanking sequence
(data not shown). A new oligonucleotide primer IV1 (5'-AGG-
TACCTCTGTTCTACCTAACCTAGA-3') was synthesized
based on nucleotides 81 to 105 bp upstream of exon 48, which
was used for PCR with primer 48B (3' end primer).
For a single strand conformation polymorphisms (SSCP)
analysis [25], the amplified DNA fragments were denatured and
electrophoresed under non-denaturing conditions on a 7.5%
polyacrylamide gel with 6% glycerol at 4°C at 100 volts for 10
hours. The DNA was detected after silver staining of the gel.
For family tracking, amplified DNAs from the patient and
family members were digested with restriction enzyme NlaIII,
and electrophoresed on a 15% polyacrylamide gel.
Fig. 3. Agarose gel electrophoresis of PCR
amplified DNAs from normal and patient
OYM. A. Strategy for PCR. Amplifications
were performed for detection of exon 47,
exon 48, and exon 49. B. Sequences of
oligonucleotide primers. See Fig. 2 in
primers 48A and 49B. C. Agarose gel (1.5%)
electrophoresis of amplified DNAs. Left,
exon 47; middle, exon 48; right, exon 49.
Lane 1, patient; lane 2, normal male control;
M, 1 kb ladder marker. Amplified DNA of
only exon 48 in the patient was not
detected.
Results
We screened one million plaque-forming units of cDNA and
obtained three duplicate positive signals. The three types of the
COL4AS cDNA isolated were named HS19, HS3, and HS2O,
spanning exons 47 to 51(0.8 kb), exons 42 to 51(1.3 kb), and
exons 39 to 51(1.7 kb), respectively (Fig. 2). Southern blot
Fig. 4. PCR-SSCP analysis of exon 48 by silver staining. The amplified
DNA fragments with primers LVI and 48B were denatured and electro-
phoresed under non-denaturing condition on a 7.5% polyacrylamide gel
with 6% glycerol at 4°C at 100 volts for 10 hours. The DNA was
detected after silver staining of the gel. Lane 1 and 3, normal male
control; lane 2, patient OYM. Compared to normal control, the mobility
of two single strand DNAs, indicated by arrowheads, was altered.
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Fig. 5. Partial nucleotide sequence of PCR amplfled DNA with primers IVJ and 48B. Left, normal male control; right, patient OYM. The
mutation in the patient proved to be a single base insertion indicated by arrows between nucleotides 4750(37) and 4751 (38). The sequence is labeled
5' and 3' in reference to orientation of the COL4A5 cDNA (parentheses: nucleotides in the exon 48).
Amino acid
positions
Mutant ATT GCC UT CAT GTT CTG CAA CAT CAAlie Ala Phe His Vai Leu Gin His Gin
analysis after digestion with EcoR! revealed no loss or change
in the restriction fragments when hybridized with eDNA HS 19,
thereby indicating the absence of any major rearrangement in
the gene from exons 47 to 51 (data not shown). PCR analysis of
part of exons showed that exon 48 was not amplified, while
exons 47 and 49 were normal (Fig. 3).
To obtain more information of exon 48 and adjacent regions,
we screened one million plaque-forming units of genomic DNA
and obtained four positive signals containing exon 48. We
isolated one genomic clone (1.5 kb) and determined the flanking
sequence (data not shown). With a combination of in vitro
amplification of exon 48 with primers IVl and 48B and SSCP
analysis, the presence of a mutation in exon 48 was suggested.
Fig. 6. The amino acid sequence and
deduced protein of the a5(IV) collagen
chain of patient OYM. Top, amino acid
numbers start at the translation initiator
methionine [11]. Parentheses: those in the
Nd domain. Middle, nucleotide and
deduced amino acid sequences in wild type
and mutant are shown by inner and outer
lines, respectively. A single base insertion is
indicated by an arrowhead, and the
premature stop codon by an asterisk.
Bottom, illustration of deduced protein of
the a5(IV) collagen chain of patient OYM.
The insertion alters the reading frame and
changes 9 amino acids 1516 to 1524, and
introduces a premature terminal signal at
codon 1525. The deduced protein would lack
about two-thirds of the NC! domain shown
by the gray box.
Compared to control samples, the mobility of the amplified
fragment of the patient was clearly altered (Fig. 4).
DNA sequencing analysis of the amplified DNA product
revealed a single base insertion (T) between nucleotides T 4750
and G 4751 [11] (between nucleotides 37 and 38 in exon 48)
within methionine 1516(60 in the NC1 domain) (Figs. 5, 6). This
finding was confirmed by repeated sequencing. The insertion
was localized between nucleotides T and G at the 3' end of
primer 48A (Fig. 2B). Thus, the failure to amplify exon 48 from
genomic DNA of the patient could be due to a mismatch in the
primer 48A and template (Fig. 3C).
When the PCR amplified DNA (282 bp) from the control was
digested with N/all! (restriction site; CATG/), five fragments
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(142, 78, 41, 12, and 9 bp) were produced. For the patient, two
fragments (142 and 9 bp) were absent and a new fragment (152
bp) appeared because of the missing first NlaIII site by a change
from CATG to CATTU in the insertion point (Fig. 7). The
patient's mother was heterozygous with the normal 142 bp
fragment and the variant 152 bp fragment, whereas the patient's
brother and one sister had the normal 142 bp fragment. DNA
samples from other members of the family could not be ob-
tamed.
Discussion
We identified a single base (T) insertion in exon 48 (NC!
domain) of the COL4A5 gene located between nucleotides 4750
and 4751. We did not detect the same insertion in 24 unrelated
Japanese patients. Several mutations have been reported
[9—17], but none was the same as ours. We propose that the
mutation we identified is a novel one in Alport syndrome. This
insertion alters the reading frame and introduces a premature
termination signal, TAA (nucleotides 4775-4778) after amino
acid 1524 (68 in the NCI domain). This mutation would be
Fig. 7. Pedigree of patient OYM and gene
tracking by restriction enzyme NlaIlI
digestion of amplified DNA. A. Pedigree of
patient OYM. Obligate female carrier is
shown as an open circle with a dot.
Unaffected female is shown as an open
circle and unaffected male as an open box.
Affected male is shown as a closed box. The
patient (112) is indicated by an arrowhead.
B. Region of amplified DNA with primers
IV! (5'-end) and 48B (3'-end) indicated by
arrows. NlaIII restriction sites in wild type
and mutant are indicated by vertical lines,
and fragment sizes by numbers (bp). The
insertion point is indicated by an asterisk.
C. Digestion of amplified DNA with NlaIII
and electrophoresed on a 15% polyacrylamide
gel. Four fragments of 78 bp and less ran off
the gel. Lane 2 (C), normal male control; lane
3 (12), mother; lane 4 (112), patient; lane 5
(113), brother; and lane 6 (Ill), sister; lane I
and 6 (M), 1 kb ladder marker. The patient
(112) is missing the 142 bp fragment and has a
variant 152 bp fragment. His mother (12) is
heterozygous with the normal 142 bp fragment
as well as the variant 152 bp fragment.
expected to result in synthesis of the truncated aS(IV) collagen
chain that differs from the normal protein in the nine amino
acids at its carboxy terminus and that lacks about two-thirds of
the NC! domain (Fig. 6). Lesions such as this mutation in the
globular NC! domain of a5(IV) collagen chain would have a
direct effect on the type IV collagen network at lamina densa in
the GBM. This part of the molecule is needed to align the three
a chains involved in the triple-helical domain to enable correct
folding [26, 27]. In addition, the NC! domain is an integral part
of the cross-linking between two adjacent triple-helical mole-
cules during formation of the type IV collagen network [28, 29].
Massive proteinuria with splitting of the lamina densa was
considered to be due to an increased permeability of GBM,
because of abnormal networks of the type IV collagen as a
result of this mutation. Rumpelt reported that the degree of
proteinuria and splitting of the lamina densa were correlated
positively in patients with Alport syndrome [30].
Gene tracking by NlaIII digestion revealed that the patient's
mother was a heterozygote of the mutant allele and wild type
allele (Fig. 7), therefore, the mutation was inherited from the
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mother. The patient's sister and younger brother carried the
wild type allele alone, though both had hematuria and protein-
uria but no audiometry and ocular abnormalities. Renal biopsy
findings of the sister showed no splitting of the lamina densa in
all fields examined. Although histological examination could
not be done in case of the brother, our observation did suggest
that a disorder other than Alport syndrome was present.
Takebayashi identified a patient with IgA nephropathy among a
large kindred with Alport syndrome (personal communication).
Without gene analysis, they would be misdiagnosed as Alport
syndrome on clinical and familial basis. We propose that
diagnosis of the disease should be made on the basis of both
clinical phenotypes and molecular defects.
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